ERBB2 and non-small cell lung carcinoma: A phase II study on an erstwhile pan-TKI, pyrotinib (administered orally) that inhibits HER1, HER2 and HER4, screened 60 advanced NSCLC sufferers having HER2 exon 20 mutations.